The global immunomodulator market size is calculated at USD 88.80 billion in 2024 and is predicted to reach around USD 179.64 billion by 2034, expanding at a CAGR of 7.3% from 2024 to 2034.
The immunomodulator market is an integral segment of the healthcare industry. Immunomodulators are substances altering the body’s immune response either by stimulating (immunostimulants) or suppressing (immunosuppresants) the immune system by acting on pathways regulating the immune system’s activity. It can take about 3 to 6 months or even longer for immunomodulators to show effect. Some examples are monoclonal antibodies, cytokines, vaccines, levamisole among others.
The rising use of immunomodulators after transplants for reducing organ rejection, availability of wide range of immune system modulators, increasing cases of patients with chronic disorders, especially with autoimmune disorders and the advancements in immunomodulatory therapy are factors driving the market growth of immunomodulators. The increasing applications of immunomodulators in cancer treatments and rising approvals of biological response modifiers is expected to fuel the market growth.
Moreover, the ongoing research and clinical trials for developing novel and effective immunotherapies as well as rising collaborations and partnerships among companies and research institutes are the factors anticipated to create opportunities for the market players in the upcoming years.
Published by Ajit Bansod
